AHA 2017 Scientific Sessions
Direct Oral Anticoagulant Use Increasing in Dialysis Patients With AFib
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
Your search for esrd returned 16 results
American College of Cardiology 2011
Lipid Management in Special Populations
Statins are the most widely prescribed agents in the world. While muscle-related adverse effects associated with statins are well known, accurately quantifying their incidence to guide clinicians with respect to lipid management can be difficult, said Richard H. Karas, MD, PhD, Tufts Medical Center, Boston, at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
AAAAI 2017
Is IL-5 Inhibition Effective in NSAIDs-Exacerbated Respiratory Disease?
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
PainWeek 2013
The Search for Clinical Inflammatory Markers for Centralized, Intractable Pain
Multiple inflammatory markers should simultaneously be tested to best detect unresolved inflammation in pain patients according to results presented at PAINWeek 2013 from a study conducted by pain specialist Forest Tennant, MD, DrPH.
ACR/ARHP Annual Meeting 2013
CZP + MTX Demonstrate Favorable Long-Term Efficacy in Active RA
At the 2013 ACR/ARHP Annual Meeting, study authors presented that patients with active rheumatoid arthritis (RA) despite methotrexate (MTX), certolizumab pegol (CZP) + MTX maintained reduction in signs and symptoms through 5 years.
CHEST 2020
Increased GERD Risk in End-Stage Lung Disease Without Esophageal Disease
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
ACR/ARHP 2016 Annual Meeting
Anti-TNF Agents Go Head-to-Head in RA Superiority Study
The trial compares short- and long-term outcomes of Cimzia and Humira in RA
ACR/ARHP Annual Meeting 2013
Twice-Daily Tofacitinib Shows Sustained Efficacy Over 5 Years in RA
Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension studies for patients with rheumatoid arthritis, as presented at the 2013 ACR/ARHP Annual Meeting.
ACR/ARHP 2016 Annual Meeting
Uveitis in Ankylosing Spondylitis: Risk Factors Identified
Uveitis should be suspected in patients with ankylosing spondylitis (AS) who have high lesion counts, antistreptolysin O (ASO) and circulating immune complex (CIC) titers
ACR/ARHP Annual Meeting 2015
Tofacitinib Efficacy Unaffected by Methotrexate Dose in RA
Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and "appeared similar regardless of methotrexate dose" in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
